Introducing the GenTAC Alliance

The GenTAC Alliance is a community of stakeholders committed to advancing our understanding of genetic thoracic aortic diseases and their treatment.

The Alliance builds upon the successes of the GenTAC Registry, which enrolled and followed participants from 2006 to 2016 and seeks to involve a much wider group of stakeholders and be more expansive in scope.

The goals of the GenTAC Alliance are to advance basic, translational and clinical research; educate and support patients, families, and clinicians; and coordinate, facilitate, and encourage the use of biospecimens and data across registries.

Upcoming GenTAC Webinar

Trice Cloud Based Imaging Platform Overview and Q&A - Click here to register!
Dr. Siddharth Prakash (Chair, Biospecimens and Data Working Group) will be hosting a webinar on Friday, April 3rd at 11am EST to explain Trice Imaging, a cloud-based platform that allows physicians to securely upload and share images/videos on collaborative research projects. The software can also overlay measurements that generate output for direct multimodality comparisons and specialized analysis. Dr. Prakash will provide an overview and Q&A to discuss Trice's capabilities and gauge the interest of the entire GenTAC Alliance in potential research applications.

Home Page_Group Shot for "Become a Part of Our Community"

Become Part of Our Community

The Alliance welcomes patients, families, clinicians, researchers, and advocacy organizations to join our community of stakeholders in promoting and enhancing collaboration in education, research, and care with regard to genetically-triggered thoracic aortic disease and related cardiac and non-cardiac complications.

Learn More

Patients, Families & Advocates

Informed by members of the Patients, Families, and Clinicians Working Group, we work to connect stakeholders with the most up-to-date and accurate information regarding thoracic aortic disease.

Explore Family Resources

ACE-inhibitors and COVID 19

There have been theoretical concerns related to the use of ACE-inhibitors and ARBS in the setting of COVID 19.

Please see the link below for current ACC recommendations (published 3/17) . Short version – they are recommending no changes in medical management at this time.

https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19